Vaxcyte (PCVX) Non Operating Income (2024 - 2026)

Vaxcyte (PCVX) has 3 years of Non Operating Income data on file, last reported at $25.2 million in Q1 2026.

• On a quarterly basis, Non Operating Income fell 37.05% year-over-year to $25.2 million in Q1 2026; TTM through Mar 2026 was $142.2 million, a 12.64% increase from a year earlier, with the FY2025 full-year figure at $157.0 million, up 48.69% from the prior year.
• Non Operating Income for Q1 2026 stood at $25.2 million, down from $27.8 million in the prior quarter.
• Over the last five years, Non Operating Income for PCVX reached as high as $59.6 million in Q2 2025 and fell as low as $19.5 million in Q1 2024.
• Historically, Non Operating Income has averaged $32.0 million across 3 years, with a median of $27.8 million in 2025.
• Across the five-year window, Non Operating Income jumped 145.68% in 2025 and tumbled 37.05% in 2026, its largest moves.
• Year by year, Non Operating Income stood at $25.1 million in 2024, then grew by 10.71% to $27.8 million in 2025, then retreated by 9.17% to $25.2 million in 2026.
• Per Business Quant data, the three most recent Non Operating Income figures were $25.2 million in Q1 2026, $27.8 million in Q4 2025, and $29.6 million in Q3 2025.